DETECTION OF TUMOR ASSOCIATED ANTIGEN, PA8-15, IN SERA FROM PANCREATIC AND GASTROINTESTINAL CARCINOMA PATIENTS

被引：2

作者：

ARAI, M

SAKAMOTO, K

OTSUKA, H

YOKOYAMA, Y

AKAGI, M

机构：

[1] Department of Surgery, Kumamoto University Medical School, Kumamoto 860, 1-1

[2] Kumamoto Chuo Hospital, Kumamoto 862, 16-1

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 1990年 / 20卷 / 02期

关键词：

MONOCLONAL ANTIBODY; PA8-15; SEROLOGICAL TEST; CANCER;

D O I：

10.1093/oxfordjournals.jjco.a039379

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A sandwich enzyme immunoassay was set up to measure tumor associated antigen (antigen PA8-15) detected by monoclonal antibody PA8-15. The cut-off value was set at 55 U/ml. Tests on 437 sera samples from patients with malignant or benign diseases yielded the following positive percentages: esophageal cancer, 9.1%; gastric cancer, 23.1%; colorectal cancer, 44.8%; hepatoma, 32.6%; biliary tract cancer, 47.5%; pancreatic cancer, 84%; lung cancer, 30.8%; breast cancer, 16%; benign diseases, 13.2%. Positive antigen PA8-15 levels in patients with gastric, colorectal and pancreatic cancers, increased with the progression of clinical stage. When antigen PA8-15 was monitored in 11 various cancer cases before and after surgery, a decrease in PA8-15 value was revealed in all resected patients postoperatively, whereas a more than 100% increase in PA8-15 values was noted in non-resected patients. Compared with CEA and CA19-9, the highest positive PA8-15 rate was seen in pancreatic cancer patients. By combining the rates of positive sera obtained with each tumor marker, the overall percentage increased. These results suggest that measuring serum PA8-15 levels will aid in serological cancer diagnoses, particularly pancreatic cancer.

引用

页码：145 / 153

页数：9

共 17 条

[1]

Iwamura T., Katsuki T., Ide K., Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9, Jpn. J. Cancer Res, 78, pp. 54-62, (1987)

[2]

Yoshimura R., Sakamoto K., Egami H., Akagi M., Immunohistochemistry of human gastrointestinal cancer-associated antigen detected by monoclonal antibody PA8-15, Jpn. J. Cancer Res, 79, pp. 255-263, (1988)

[3]

Guesdon J.L., Ternynck T., Avrameas S., The use of avidin-biotin interaction in immunoenzymatic techniques, J. Histochem. Cytochem, 27, pp. 1131-1139, (1979)

[4]

Del Villano B.C., Brennan S., Brock P., Bucher C., Liu V., McClure M., Rake B., Space S., Westrik B., Schoemaker H., Zurawski V.R., Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA19-9, Clin. Chem, 29, pp. 549-552, (1983)

[5]

Booth S.N., King J.P.G., Leonard J.C., Dykes P.W., Serum carcinoembryonic antigen in clinical disorders, Gut, 14, pp. 794-799, (1973)

[6]

Haga Y., Sakamoto K., Egami H., Yoshimura R., Akagi M., Evaluation of serum CA125 values in healthy individuals and pregnant women, Am. J. Med. Sci, 292, pp. 25-29, (1986)

[7]

Laurence D.J.R., Stevens U., Bettelheim R., Dar-Cy D., Leese C., Turberville C., Alexander P., John E.W., Neville A.M., Role of plasma carcinoembryonic antigen in diagnosis of gastrointestinal, mammary and bronchial carcinoma, Br. Med. J, 3, pp. 605-609, (1972)

[8]

Jalanko H., Kuusela P., Roberts P., Haglund C., Makela O., Comparison of a new tumor marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases, J. Clin. Pathol, 37, pp. 218-222, (1984)

[9]

Dilawari J.B., Philippakos D., Blendis L.M., Waller S.L., Carcinoembryonic antigen in differential diagnosis of carcinoma of pancreas from chronic pancreatitis, Br. Med. J, 21, (1975)

[10]

Cooper M.J., Marchie C.R., Skinner D.B., Moosa A.R., A reappraisal of the value of carcinoembryonic antigen in the management of patients with various neoplasms, Br. J. Sur, 66, pp. 120-123, (1979)

← 1 2 →